Alzheimer’s Care Moves Toward AI‑Driven Personalization Amid Medicare Policy Debate

South Korean biotech NeuroXT and Boston’s Beth Israel Deaconess Medical Center have expanded a research partnership to use artificial‑intelligence analysis of MRI scans for predicting individual responses to Alzheimer’s therapies. Building on a 2024 pilot that validated NeuroXT’s AI biomarkers against PET imaging, the new phase will examine longitudinal patient data to identify which treatments are most likely to benefit each patient, aiming to make advanced diagnostics more scalable and affordable.

In the United States, Medicare’s Coverage with Evidence Development policy requires patients to enroll in government‑approved studies before receiving approved Alzheimer’s drugs, prompting many private insurers to deny coverage. Critics argue the red tape increases costs for families, who already shoulder roughly 70% of the $400,000 lifetime care burden, while Medicare spends $174 billion annually on Alzheimer’s care. The controversy highlights the tension between regulatory requirements and the promise of personalized, AI‑enhanced treatment pathways.